Table IV.

Role of effector cell-derived IFN-γ on day 7 effector cell therapy following B16-OVA tumor challengea

Effector Cell TherapyMean Survival Time ± SEM (Days)
Wild-type Tc154.0 ± 3.5∗
OT-I.IFN-γ Tc142.8 ± 1.5∗,∗∗
Wild-type Tc258.6 ± 8.3∗
OT-I.IFN-γ Tc245.2 ± 2.2∗
Untreated30.8 ± 0.5
  • a Mice (n = 8/group) were injected i.v. with 5 × 105 B16-OVA tumor cells. OVA-specific Tc1 or Tc2 effector cells, generated from either OT-I.IFN-γ or wild-type OT-I mice, were adoptively transferred into mice bearing 7-day established lung metastases. p value for treated animals vs untreated animals: ∗, p < 0.008; p value for IFN-γ-deficient effector cell treatment vs corresponding wild-type effector cell treatment: ∗∗, p < 0.05.